Literature DB >> 26948327

Individualized CT Angiography Protocols for the Evaluation of the Aorta: A Feasibility Study.

Madeleine Kok1, Michael W de Haan2, Casper Mihl1, Nienke G Eijsvoogel2, Babs M F Hendriks2, Anna M Sailer3, Kris Derks2, Roald S Schnerr2, Geert Willem H Schurink4, Joachim E Wildberger1, Marco Das5.   

Abstract

PURPOSE: Ionizing radiation and iodinated contrast media are potential drawbacks to repetitive follow-up CT angiography in current practice. The aim of the present study was to optimize radiation dose and contrast agent volume by using individualized CT angiography protocols.
MATERIALS AND METHODS: Eighty consecutive patients referred for CT angiography of the whole aorta were prospectively evaluated. Patients were divided into groups of patients with a body mass index (BMI) < 28 kg/m(2) (group 1; n = 50) and those with a BMI ≥ 28 kg/m(2) (group 2; n = 30). A control group consisted of 50 consecutive patients who were retrospectively evaluated. CT angiography parameters on a second-generation dual-source scanner were 128 × 0.6-mm collimation, pitch of 0.9, rotation time of 0.33 seconds, tube voltages of 80/100/120 kVp (group 1/group 2/control), reference tube current of 400 mA, and image reconstruction at 1-mm/0.8-mm slice thickness (kernels, B30f [control] and I30f/strength 3 [groups 1/2]). The control group received 120 mL of contrast agent (300 mgI/mL) at 4.8 mL/s; groups 1 and 2 received 44 mL and 53 mL at 3.3 mL/s and 4 mL/s, respectively. Effective dose was evaluated for each patient. Image quality was determined by qualitative image analysis at the levels of the thoracic, abdominal, and pelvic aorta as nondiagnostic, diagnostic, good, or excellent, and quantitative image analysis was performed, including attenuation values and contrast-to-noise ratio (CNR).
RESULTS: Mean effective radiation dose values for CT angiography of the aorta were 3.7 mSv ± 0.7 in group 1, 6.7 mSv ± 1.4 in group 2, and 8.7 mSv ± 1.9 in the control group (P < .001). Mean attenuation values and CNR levels were 334 HU ± 66 and 16 ± 8, respectively, in group 1, 277 HU ± 56 and 14 ± 5 in group 2, and 305 HU ± 77 and 11 ± 4 in the control group.
CONCLUSIONS: Iterative reconstruction algorithms resulted in 23%-57% less radiation in combination with 55%-63% less contrast agent volume compared with standard CT protocols.
Copyright © 2016 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26948327     DOI: 10.1016/j.jvir.2016.01.009

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  4 in total

1.  CT Angiography in the Lower Extremity Peripheral Artery Disease Feasibility of an Ultra-Low Volume Contrast Media Protocol.

Authors:  Barbora Horehledova; Casper Mihl; Gianluca Milanese; Rutger Brans; Nienke G Eijsvoogel; Babs M F Hendriks; Joachim E Wildberger; Marco Das
Journal:  Cardiovasc Intervent Radiol       Date:  2018-05-22       Impact factor: 2.740

2.  The role of standard non-ECG gated chest CT in cardiac assessment: design and rationale of the Cardiac Pathologies in standard chest CT (CaPaCT) study.

Authors:  Nienke G Eijsvoogel; Babs M F Hendriks; Hugo B Park; Sibel Altintas; Casper Mihl; Barbora Horehledova; Bastiaan L J H Kietselaer; Harry J G M Crijns; Joachim E Wildberger; Marco Das
Journal:  Eur Radiol Exp       Date:  2018-04-27

3.  Retrospectively ECG-gated helical vs. non-ECG-synchronized high-pitch CTA of the aortic root for TAVI planning.

Authors:  Barbora Horehledova; Casper Mihl; Ellen Boswijk; Genevieve A J C Crombag; Estelle C Nijssen; Patty J Nelemans; Leo F Veenstra; Joachim E Wildberger; Marco Das
Journal:  PLoS One       Date:  2020-05-12       Impact factor: 3.240

4.  Personalization of CM Injection Protocols in Coronary Computed Tomographic Angiography (People CT Trial).

Authors:  N G Eijsvoogel; B M F Hendriks; P Nelemans; C Mihl; J Willigers; B Martens; J E Wildberger; M Das
Journal:  Contrast Media Mol Imaging       Date:  2020-01-17       Impact factor: 3.161

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.